BioDtec Soybeans Biotechnology Detection Automation

| October 24, 2014

article image
BIODTEC: An efficient automation that processes soybeans (or other grain) samples, detects and identify biotechnologies presence and broadcast results information to multiple recipients all in 3 minutes time per sample. Its size, similar to a PC CPU, makes it ideal for labs uses on elevators and ports facilities.

Spotlight

Worthington Biochemical Corporation

Worthington is a privately owned, ISO9001 Certified. primary manufacturer of high-quality purified enzymes, proteins, nucleic acids and kits for biotech and life science research, diagnostic, biopharmaceutical and bioprocessing applications. Our reputation for producing quality products for all types of life science applications is the result of over 65 years of experience. Worthington’s in-house, full-service capabilities include initial extraction, fermentation, protein purification, lyophilization and packaging. All processes are fully documented and traceable from raw materials through final shipment.

OTHER ARTICLES

2 Small-Cap Biotech Stocks You Haven't Heard of, But Should Know About

Article | April 17, 2020

With everything that's going on with the COVID-19 pandemic, many healthcare companies have grabbed plenty of spotlight during these challenging times. At the same time, a number of otherwise promising businesses have slipped under the radar. That's especially true for small-cap biotech stocks that aren't actively involved in developing tests, vaccines or treatments for COVID-19. Vaccine developers, protective equipment producers, and healthcare service providers are all attracting plenty of attention during this pandemic, but there are just as many promising biotech stocks that aren't involved in these areas. Here are two such companies that you might have missed, but they deserve a spot on your watch list.

Read More

Wisconsin biotech companies could play key roles in long-term economic recovery from COVID-19 pandemic

Article | April 19, 2020

Whether it’s called a modern “Manhattan Project” or a medical moon shot, the concept of long-term economic recovery rests on how confident people are they won’t risk serious illness by venturing forth in public again. Wisconsin stands to be a significant part of such an undertaking, whatever it’s called. The shorter-term debate is well under way over the gradual lifting of COVID-19 emergency rules, such as the now-extended “safer-at-home” order in Wisconsin. At least a dozen states, including regional coalitions on the East and West coasts, are exploring next steps as they seek to balance responses to the virus with calls for reopening the economy, at least, in part. Wisconsin’s ability to shape longer-term responses will come from private and public resources, which range from companies engaged in production of diagnostics.

Read More

5 Biotech Stocks Winning the Coronavirus Race

Article | April 13, 2020

There are quite a few companies that have found ways to grow their business during the ongoing COVID-19 pandemic. This is especially true for a number of biotechs now working on developing a potential treatment for, or vaccine against, the virus; shares of such companies have largely surged over the past couple of months. Although many of these treatments and vaccines are still have quite a way to go before they're widely available, it's still worth taking some time to look through what's going on in the COVID-19 space right now. Here are five biotech stocks that are leading the way when it comes to addressing COVID-19. Regeneron Pharmaceuticals (NASDAQ:REGN) wasn't among the initial wave of companies to announce a potential COVID-19 drug. However, investor excitement quickly sent shares surging when the company announced that its rheumatoid arthritis drug, Kevzara, could help treat COVID-19 patients.

Read More

Pfizer, BioNTech Plan Clinical Trial for COVID-19 mRNA Vaccine Candidate

Article | April 9, 2020

Pfizer and BioNTech plan to begin human clinical trials on their lead COVID-19 therapeutic candidate, an mRNA vaccine, by the end of this month, the companies said today, through a collaboration that could generate up to $748 million for the German biotech. The companies announced plans last month to partner on BNT162, the first treatment to emerge from BioNTech’s accelerated COVID-19-focused development program, “Project Lightspeed.” BioNTech and Pfizer established collaboration intended to draw upon BioNTech’s proprietary mRNA vaccine platforms, and Pfizer’s expertise in vaccine research and development, regulatory capabilities, and global manufacturing and distribution network.

Read More

Spotlight

Worthington Biochemical Corporation

Worthington is a privately owned, ISO9001 Certified. primary manufacturer of high-quality purified enzymes, proteins, nucleic acids and kits for biotech and life science research, diagnostic, biopharmaceutical and bioprocessing applications. Our reputation for producing quality products for all types of life science applications is the result of over 65 years of experience. Worthington’s in-house, full-service capabilities include initial extraction, fermentation, protein purification, lyophilization and packaging. All processes are fully documented and traceable from raw materials through final shipment.

Events